TCR Gene Therapy in Pancreatic Cancer | NEJM
5 意见
• 07/13/23
0
0
嵌入
Pancreatic cancer is resistant to most forms of therapy but may be vulnerable to T cells that recognize a “hot-spot” mutation — KRAS G12D — commonly found in that cancer. New research findings are summarized in a short video.
To see the full article, follow this link: https://nej.md/3wS9STm
显示更多
脸书评论
SORT BY-
热门评论
-
最新评论